Elanco Animal Health Inc

ELAN

Add to Watchlist

23.650USD

-0.365-1.52%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

Elanco Animal Health Inc's Score

Industry at a Glance

Industry Ranking

24 / 156

Overall Ranking

90 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Elanco Animal Health Inc Highlights

StrengthsRisks

Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -48.45, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 547.53M shares, decreasing 11.69% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 7.09K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

29.846

Target Price

+24.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Elanco Animal Health Inc is 7.31, ranking 114 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.37B, representing a year-over-year increase of 14.92%, while its net profit experienced a year-over-year increase of 14.93%.

Score

Industry at a Glance

Previous score

7.31

Change

0



Financials

5.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.46

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.27

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Elanco Animal Health Inc is 7.41, ranking 70 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is -48.45, which is -852.83% below the recent high of 364.72 and -342.53% above the recent low of -214.39.

Score

Industry at a Glance

Previous score

7.41

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/156

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Elanco Animal Health Inc is 8.63, ranking 21 out of 156 in the Pharmaceuticals industry. The average price target is 25.00, with a high of 30.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.63

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Elanco Animal Health Inc is 7.39, ranking 53 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 26.09 and the support level at 21.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.57

Change

-0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Elanco Animal Health Inc is 10.00, ranking 1 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 109.64%, representing a quarter-over-quarter decrease of 8.96%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 79.08M shares, representing 15.83% of shares outstanding, with 5.16% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

79.08M

-4.44%

PRIMECAP Management Company

Star Investors

46.21M

-7.49%

BlackRock Institutional Trust Company, N.A.

40.81M

+0.96%

Fidelity Management & Research Company LLC

39.05M

-23.03%

T. Rowe Price Investment Management, Inc.

35.23M

+11.80%

Dimensional Fund Advisors, L.P.

25.08M

+1.51%

State Street Investment Management (US)

15.05M

-1.28%

Fidelity Institutional Asset Management

12.16M

-0.55%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Elanco Animal Health Inc is 7.85, ranking 33 out of 156 in the Pharmaceuticals industry. The company's beta value is 1.70. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Elanco Animal Health Inc

ELAN

7.93 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.80 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Collegium Pharmaceutical Inc

COLL

8.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment